Arbor Pharmaceuticals, Inc. Announces Agreement with Accentia Biopharmaceuticals, Inc. to Launch Company's Second Pediatric Treatment

Share Article

Arbor Pharmaceuticals, Inc. Announces Agreement with Accentia Biopharmaceuticals, Inc. to Launch Company's Second Pediatric Treatment. Companies will collaborate to promote NEOTIC™ to pediatricians and ENTs throughout US.

Arbor Pharmaceuticals, Inc. announced that the company has entered into a sales and marketing agreement with Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) to launch and promote the company's second prescription product throughout the US. Neotic™, Arbor's patented prescription ear medication, will treat the pain and inflammation associated with middle ear infections and will be promoted by Accentia's US-based specialty sales force to pediatricians and ENTs.

This sales and marketing agreement is Arbor Pharmaceuticals' second promotional collaboration with Accentia and marks another important milestone in the company's growth plan. In 2007 Arbor successfully launched its first product - Zinotic® - for swimmer's ear and has demonstrated significant sales growth since its introduction.

"Arbor Pharmaceuticals is very pleased to be working with Accentia Biopharmaceuticals to bring Neotic™ to the market. Accentia is the ideal partner for Arbor as they are an established specialty pharmaceutical company with a strong orientation toward those physicians who treat the majority of ear infections in the US. We are confident that this collaboration will be beneficial to both companies and will serve to introduce an important new product to pediatricians and ENTs for the millions of children that suffer from acute otitis media," says Jarrett Disbrow, President and Chief Executive Officer of Arbor Pharmaceuticals.

Accentia Biopharmaceuticals also announced the Neotic™ collaboration. Accentia Chairman and CEO Frank O'Donnell, Jr., MD noted that "Accentia continues to build its specialty pharmaceuticals sales and marketing division with the addition of Neotic™. This is an important agreement for both companies as we both continue to execute on our business plans."

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joshua Disbrow
Visit website